Aerie Pharmaceuticals Inc.

Aerie Pharmaceuticals — Investor Presentation (March 2020)

25 slides from Aerie Pharmaceuticals's investor presentation, Mar 2, 2020

  1. Slide 1: Company Overview Investor Presentation March 2020

    Company Overview Investor Presentation March 2020 Exhibit 99.1

  2. Slide 2: Important Information

    For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified

  3. Slide 3: Aerie Overview

    Aerie Overview Rhopressa® and Rocklatan® have not been approved by any regulatory authority other than the FDA. Additional potential Rhopressa® indications are being considered for further study and are not labeled indications. AR-13503 and AR-1105 are development stage product candidates and are no

  4. Slide 4: Glaucoma Market Perspective

    Glaucoma Market Perspective Sources: IQVIA: NPA Rx and NSP Unit data For Investor Use - ~$3B Market, 36M TRx, 55M bottles - 55% of unit volume first-line (PGAs) - 45% of unit volume 2-3X/Day Adjuncts 2019 U.S. Glaucoma Market Graph Source: IQVIA 2019 CAI: Carbonic Anhydrase Inhibitor AA: Alpha Agoni

  5. Slide 5: Rocklatan Phase 3 Month 12 Responder Analysis

    For Investor Use Rocklatan® Phase 3 Month 12 Responder Analysis: Goal is to Achieve Lowest IOP Possible At Month 12: % of Patients with IOP Reduced to 18 mmHg or Lower *p<0.05, **p<0.01, ***p<0.0001 ++Data on File Based on Mercury 1 Interim Analysis 2 Rocklatan® has not been approved by any regulato

  6. Slide 6: Topline Results from Rhopressa Phase 4 Multi-center Open-label Study (MOST)

    Topline Results from Rhopressa® Phase 4 Multi-center Open-label Study (MOST) 12-week MOST study evaluated efficacy, tolerability and safety of Rhopressa® use in 260 patients in a real-world clinical setting Use of Rhopressa® as monotherapy or adjunct was at discretion of the physician Used adjunctiv

  7. Slide 7: U.S. Glaucoma Franchise Launch Update

    For Investor Use U.S. Glaucoma Franchise Launch Update Rhopressa® and Rocklatan® have not been approved by any regulatory authority other than the FDA. Actual Weekly Sales-Out to Pharmacies Data as of 2/28/20 IQVIA Weekly Data as of 2/21/20 1/4/2019 1/4/2019 2/21/20 2/28/20 16,872 11,357 14,180 10,4

  8. Slide 8: U.S. Glaucoma Franchise: TRx/NRx as of 2/21/20

    U.S. Glaucoma Franchise: TRx/NRx as of 2/21/20 % TRx Change vs. Last Week % NRx Change vs. Last Week Rhopressa® 3.9% 1.9% Rocklatan® 2.2% -1.0% Franchise 3.4% 0.9% Market 0.5% -0.6% For Investor Use

  9. Slide 9: Market Access as of March 2020

    For Investor Use Market Access as of March 2020 Access percentages reflect signed contracts, not necessarily implemented underlying formulary coverage. Rhopressa® Commercial ~ 90% of covered lives Medicare Part D ~ 75% of covered lives Rocklatan® Commercial ~ 82% of covered lives Medicare Part D ~ 3

  10. Slide 10: Active Engagement at Key Conferences

    For Investor Use Active Engagement at Key Conferences February 2020: American Glaucoma Society (AGS) May 2020: Association of Research in Vision and Ophthalmology (ARVO) May 2020: American Society of Cataract and Refractive Surgeons (ASCRS) May/June 2020: European Glaucoma Society (EGS) July 2020: A

  11. Slide 11: Expanding Aerie Franchise: Europe

    For Investor Use Expanding Aerie Franchise: Europe Marketing authorisation granted for Rhokiinsa® (Rhopressa®) in November 2019; Roclanda® (Rocklatan®) MAA accepted for review in December 2019 Mercury 3: 6-month safety and 90-day efficacy registration trial comparing Rocklatan® (known as Roclanda® i

  12. Slide 12: Expanding Aerie Franchise: Japan

    For Investor Use Expanding Aerie Franchise: Japan Phase 2 study successful top-line results released in November 2019 Phase 3 trials expected to be conducted in Japan Sources: IQVIA Analytics Link at ex-manufacturer price level – March 2019. *TRx calculated from IQVIA unit data (1 month = 1 TRx) Aer

  13. Slide 13: AR-13324-CS208 Japan Phase 2 Study Topline Results

    AR-13324-CS208 Japan Phase 2 Study Topline Results 28-day prospective, double-masked, placebo-controlled, dose-ranging study of netarsudil efficacy and safety in Japanese subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) Netarsudil 0.01%, 0.02% and 0.04% were efficacious, met prim

  14. Slide 14: Advancing the Pipeline

    For Investor Use Advancing the Pipeline Drug/Target Indication Development Stage Preclinical Phase 1/2a Phase 2b Front of the Eye AR-15512 (AVX TRPM8 agonist) Dry Eye Back of the Eye AR-1105 Implant (Dexamethasone) RVO/DME AR-13503 Implant (ROCK, PKC) wAMD DME/DR Glaucoma Neuro- enhancement

  15. Slide 15: U.S. Dry Eye Market

    For Investor Use U.S. Dry Eye Market Estimated 30 million dry eye sufferers in the United States Less than 3 million treated Sources: Mixture of public information, IQVIA , Market Scope and estimates – Feb 2020 US 2019 Sales: $1.6B est.

  16. Slide 16: AVX-012 for Dry Eye

    For Investor Use AVX-012 for Dry Eye Novel Mechanism of Action – Modulation of Corneal TRPM8 receptors TRPM8 receptor is a cold thermoreceptor involved in basal tear production (i.e.; sign) Modulation of TRPM8 also provides a cooling sensation upon instillation (i.e.; symptom) This mechanism of acti

  17. Slide 17: AVX-012 (TRPM8 Agonist) for Dry Eye

    AVX-012 (TRPM8 Agonist) for Dry Eye For Investor Use

  18. Slide 18: AVX-012 Dry Eye Clinical Trial Highlights

    AVX-012 Dry Eye Clinical Trial Highlights Significant efficacy achieved for sign and symptoms with BID dosing of 0.0014% (50µM) AVX-012 over 28 days Sign: Schirmer Evaluation Percentage of patients improving ≥3mm Symptoms: SANDE Score Percentage of patients improving ≥20 score For Investor Use ++Dat

  19. Slide 19: Bringing Small Molecule Therapy to Back of the Eye

    Bringing Small Molecule Therapy to Back of the Eye Most retinal drugs in use and in pipeline are protein therapeutics Longer half-life allows monthly to bimonthly IVT injections Protein therapeutics address limited number of extracellular targets Small molecules address a wider array of therapeutic

  20. Slide 20: Aerie's Ophthalmic Implant Platform

    For Investor Use Aerie’s Ophthalmic Implant Platform Small Molecule Drug Candidates Proprietary Drug Delivery Technology Bio-erodible, sustained-release implant for intravitreal injection DSM PEA Polymer PLGA PRINT® Mfg AMD DME RVO Dry AMD/GA Glaucoma Others Aerie Kinase Library Non-Aerie drug candi

  21. Slide 21: 2019 U.S. Retinal Disease Market

    For Investor Use 2019 U.S. Retinal Disease Market Sources: Mixture of public information, IQVIA, Market-Scope and estimates – Feb 2020 2019 Sales: $6.8B 2019 Unit Sales: 8.1MM

  22. Slide 22: Aerie's Sustained Implant Opportunities

    For Investor Use Aerie’s Sustained Implant Opportunities Markets in Need of Further Innovation: Retinal Vein Occlusion (RVO) Wet Age Related Macular Edema (wAMD) Diabetic Macular Edema (DME) Broadly Underserved Market Opportunities: Glaucoma Neuro-enhancement Dry AMD/Geographic Atrophy (GA)

  23. Slide 23: Aerie's Lead Implant Product Candidates

    For Investor Use Aerie’s Lead Implant Product Candidates AR-1105 (Dexamethasone) Implant (Phase 2 readout ~ H2 2020) Indications under development: retinal vein occlusion (RVO) Target product profile vs. Ozurdex® Designed for longer duration of efficacy (6 mo vs 3 mo) Designed for improved administr

  24. Slide 24: Aerie's Key Catalysts for 2020

    Aerie’s Key Catalysts for 2020 Pipeline: Avizorex TRPM8 agonist for Dry Eye Phase 2/3 clinical study expected to commence H2 2020 AR-1105 Phase 2 RVO clinical study readout expected H2 2020 AR-13503 clinical study for Neuro-enhancement expected to commence H2 2020 Globalization: Roclanda® Mercury 3

  25. Slide 25: Summary Key Priorities

    For Investor Use Summary Key Priorities Successful commercialization in U.S. of Rhopressa® and Rocklatan® Globalization Strategy Europe/Japan clinical path and commercialization strategy Ireland Manufacturing Facility – expected to be online H1 2020 Research Initiatives Avizorex TRPM8 agonist for dr

Aerie Pharmaceuticals — Investor Presentation (March 2020) on 6ix